The Temple News highlighted phase 1 study results for KLS-13019, a cannabidiol-like molecule that has potential as a non-opioid alternative in the prevention and reversal of chemotherapy-induced neuropathic pain. Sara Jane Ward, PhD, Assistant Professor of Pharmacology at the Lewis Katz School of Medicine at Temple University, has been working with KannaLife Sciences, Inc., the biopharmaceutical company that patented KLS-13019, on the animal model portions of the research. She offered insight to the Temple News for their article on the subject.
Important announcement concerning Temple Health and Keystone First. Our provider agreement with Keystone First is scheduled to end on July 31st. Click the link below to learn about your options for continuing care at Temple Health.
Learn More
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH